ISHL 2016: Featuring Brentuximab Vedotin in 21 Presentations

Over the last decade, the 10th International Symposium on Hodgkin Lymphoma (ISHL10) taking place at the Gürzenich in Cologne, Germany, October 22-25, 2016, this year hosted by the German Hodgkin Study Group (GHSG), has become the central forum for clinicians and scientists for a comprehensive exchange of up-to-date results and new treatment ideas, discussing the relevance of new findings for daily clinical practice in Hodgkin lymphoma.

seattlegenetics_logo2ISHL10 is expected to cover the most recent results in basic research, diagnostics and treatment of Hodgkin Lymphoma and related malignancies. In addition to the scientific program, a number of Satellite symposia and scientific workshops will complement the program.

During the symposium, data of Seattle Genetics’ brentuximab vedotin (Adcetris®) will be featured in 21 presentations broadly across Hodgkin lymphoma disease settings:

  • Immune Systems Engagement Results in Non-Classical Antibody-Drug Conjugate Antitumor Activity of Brentuximab Vedotin (Abstract #P099, poster presentation);
  • Evaluation of Serum TARC Levels in Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma: Results from the AETHERA Trial (Abstract #P060, poster presentation);
  • Brentuximab Vedotin After Autologous Stem Cell Transplant Yields the Strongest Benefit in Hodgkin lymphoma Patients with ≥ 2 Risk Factors: Results of a Multivariate Analysis (Abstract #P089 , poster presentation);
  • Brentuximab Vedotin Alone and in Combination With Dacarbazine or Bendamustine in Patients Aged ≥60 Years With Newly Diagnosed Hodgkin Lymphoma: Interim Results of a Phase 2 Study (Abstract #P023, poster presentation);
  • adcetris 50mg box 0001Brentuximab Vedotin Plus Bendamustine as a Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma (Abstract #P082, poster presentation);
  • PET Adapted Dose Escalation of Brentuximab Vedotin as First Line Salvage Therapy in Relapse/Refractory HL (Abstract #P083, poster presentation);
  • Post Transplant Outcomes in a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to ASCT (Abstract #P086, poster presentation);
  • Pharmacokinetics, Immunogenicity and Safety of Weekly Dosing of Brentuximab Vedotin in Pediatric Patients with Hodgkin Lymphoma (Abstract #P067, oral presentation);
  • A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (Abstract #P080, poster presentation);
  • The Pharmacokinetic and Pharmacodynamic Properties of Brentuximab Vedotin in a Patient Undergoing Hemodialysis (Abstract #P098, poster presentation);
  • Single-Arm Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin lymphoma who are Ineligible for Stem Cell Transplantation or Multiagent Chemotherapy (Abstract #P104, poster presentation);
  • Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin lymphoma: a Phase 1 Dose-Escalation study (Abstract #T024, oral presentation);
  • Preliminary Results of a Phase II Study of Brentuximab Vedotin Using a Response Adapted Design in the First Line Treatment of Patients with Hodgkin lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity (BREVITY) (Abstract #P002, poster presentation);
  • Real-World Effectiveness of Brentuximab Vedotin vs. Other Treatments in Patients with Relapsed/Refractory Hodgkin Lymphoma post Autologous Stem-Cell Transplantation (Abstract #P094, poster presentation);
  • Brentuximab Vedotin in Patients who are Ineligible for Autologous Stem Cell Transplant with Relapsed or Refractory Hodgkin Lymphoma: A UK and Germany Retrospective Study (Abstract #P093, poster presentation);
  • Risk Factors for Relapse in Patients with Relapsed or Refractory Hodgkin Lymphoma after Autologous Stem Cell Transplant: A Real-World Analysis in Germany and the United Kingdom (Abstract #P095, poster presentation);
  • Superiority of Modified Progression Free Survival to Evaluate Chemotherapy Effectiveness for Advanced Stage Hodgkin Lymphoma (Abstract #P007, poster presentation);
  • Sequential Brentuximab Vedotin and Adriamycin, Vinblastine and Darabazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma: Findings from a Phase II Window study (Abstracts #P001, poster presentation)
  • PET-adapted Therapy with Brentuximab Vedotin and Augmented ICE for Relapsed/Refractory Hodgkin Lymphoma – Lack of Improvement with 3 versus 2 Cycles of Weekly BV (Abstract #P088, poster presentation);
  • An International Multicenter Phase I/II Study of Brentuximab Vedotin and Bendamustine in Patients with Heavily Treated Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large T-Cell Lymphoma (Abstract #P085, poster presentation);
  • HALO Study: a Phase 1/2 Clinical Trial of Brentuximab Vedotin and Bendamustine in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (Abstract #P011, poster presentation).